Structural RNA and viral sequence analysis

Eric Nawrocki


Intramural Research Program National Library of Medicine National Institutes of Health



Two main areas of my research:

- 1. Viral sequence analysis tools, since 2015
- 2. Structural RNA analysis tools, since 2004

GenBank indexers handle incoming sequence submissions



SOFTWARE Open Access


VADR: validation and annotation of virus sequence submissions to GenBank




Alejandro A. Schäffer^{1,2}, Eneida L. Hatcher², Linda Yankie², Lara Shonkwiler^{2,3}, J. Rodney Brister², Ilene Karsch-Mizrachi² and Eric P. Nawrocki^{2*}

- general tool for reference-based annotation of viral sequences
- used for Norovirus and Dengue virus submissions since 2018
- used for SARS-CoV-2 submissions since March 2020
- currently also used manually for RSV, Mpox, and some Influenza submissions

VADR assists GenBank indexers: Each sequence PASSes or FAILs



Indexers decide fate of some FAILing sequences but some are sent directly back to submitter with error reports




VADR proceeds over four stages to validate and annotate sequences

- For each sequence *S*:
 - 1. Classification: compare S to all models to find best matching model M
 - 2. Coverage determination: search M against S to find 'hits'
 - 3. Alignment: align S to M and map features from M to S
 - 4. **Protein validation**: compare predicted CDS in S to proteins from M using BLASTX

Different types of alerts are identified and reported at each stage


Stage 3: Alignment and feature mapping

Align each sequence to its best-matching model



Stage 3: Alignment and feature mapping

Align each sequence to its best-matching model



| l | | |
|----------------|--|--|
| NC_001477 S | | early stop codon in CDS (cdsstopn alert) |

| code | S/F | error message | description |
|---|--------|---------------------------------|---|
| Fatal alerts | detect | ed in the annotation stage | |
| unexdivg* | S | UNEXPECTED_DIVERGENCE | sequence is too divergent to confidently assign nucleotide-based annotation |
| noftrann* | S | NO_FEATURES_ANNOTATED | sequence similarity to homology model does not overlap with any features |
| mutstart | F | MUTATION_AT_START | expected start codon could not be identified |
| mutendcd | F | MUTATION_AT_END | expected stop codon could not be identified, predicted CDS stop by |
| | | | homology is invalid |
| mutendns | F | MUTATION_AT_END | expected stop codon could not be identified, no in-frame stop codon |
| | | | exists 3' of predicted valid start codon |
| mutendex | F | MUTATION_AT_END | expected stop codon could not be identified, first in-frame stop codon |
| | _ | | exists 3' of predicted stop position |
| unexleng | F | UNEXPECTED_LENGTH | length of complete coding (CDS or mat_peptide) feature is not a multiple |
| | _ | 606 446 6700 60004 | of 3 |
| cdsstopn | F | CDS_HAS_STOP_CODON | in-frame stop codon exists 5' of stop position predicted by homology |
| | _ | DEDTIDE TOANICI ATION DOOD! EAA | to reference |
| peptrans | F | PEPTIDE_TRANSLATION_PROBLEM | mat_peptide may not be translated because its parent CDS has a problem |
| pepadjcy | F | PEPTIDE_ADJACENCY_PROBLEM | predictions of two mat_peptides expected to be adjacent are not adjacent |
| indfantn | | INDEFINITE_ANNOTATION | nucleotide-based search identifies CDS not identified in protein-based search |
| indf5gap | F | INDEFINITE_ANNOTATION_START | alignment to homology model is a gap at 5' boundary |
| indf5loc | F | INDEFINITE_ANNOTATION_START | alignment to homology model has low confidence at 5' boundary |
| indf3gap | F | INDEFINITE_ANNOTATION_START | alignment to homology model is a gap at 3' boundary |
| indf3loc | F | INDEFINITE_ANNOTATION_END | alignment to homology model has low confidence at 3' boundary |
| lowsim5f | F | LOW_FEATURE_SIMILARITY_START | region within annotated feature at 5' end of sequence lacks significant |
| 10003111131 | ' | E COVER EAR ONE SHARE | similarity |
| lowsim3f | F | LOW_FEATURE_SIMILARITY_END | region within annotated feature at 3' end of sequence lacks significant |
| .5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | • | 20112. 2711 011220111127111171 | similarity |
| lowsimif | F | LOW_FEATURE_SIMILARITY | region within annotated feature lacks significant similarity |

VADR used for Norovirus and Dengue virus sequences since 2018

| | Norovirus | Dengue virus |
|-----------------------------------|-----------|--------------|
| length | 7.6Kb | 10.7Kb |
| # seqs | 44,936 | 113,211 |
| % seqs full length | 5.1% | 8.4% |
| % Ns | 0.5% | 0.2% |
| % seqs with stretch of $>= 50$ Ns | 1.0% | 0.4% |
| average % identity | 81.6% | 94.4% |
| VADR v1.0 performance | | |
| seconds per sequence | 42.4 | 92.6 |
| required RAM | 8Gb | 8Gb |

1.1

10.2

total running time, CPU days

SARS-CoV-2 sequence submissions have increased since early 2020

| | | #new | #cumulative |
|-------|------|---------|-------------|
| month | year | seqs | seqs |
| Jan | 2020 | 32 | 32 |
| Feb | 2020 | 58 | 90 |
| Mar | 2020 | 332 | 422 |
| Apr | 2020 | 1541 | 1963 |
| May | 2020 | 2974 | 4937 |
| Jun | 2020 | 3394 | 8331 |
| Jul | 2020 | 3604 | 11,935 |
| Aug | 2020 | 3818 | 15,753 |
| Sep | 2020 | 6731 | 22,484 |
| Oct | 2020 | 11,939 | 34,423 |
| Nov | 2020 | 4274 | 38,697 |
| Dec | 2020 | 4530 | 43,227 |
| Jan | 2021 | 8775 | 52,002 |
| Feb | 2021 | 26,078 | 78,080 |
| Mar | 2021 | 42,607 | 120,687 |
| Apr | 2021 | 97,095 | 217,782 |
| May | 2021 | 104,729 | 322,511 |
| Jun | 2021 | 46,187 | 368,698 |
| Jul | 2021 | 43,336 | 412,034 |
| Aug | 2021 | 141,958 | 553,992 |
| Sep | 2021 | 267,562 | 821,554 |
| Oct | 2021 | 239,296 | 1,060,850 |
| Nov | 2021 | 267,270 | 1,328,120 |
| Dec | 2021 | 288,771 | 1,616,891 |
| Jan | 2022 | 258,522 | 1,875,413 |
| Feb | 2022 | 230,322 | 2,105,598 |
| | | =00,=00 | =,=00,000 |


SARS-CoV-2 sequences differ from Norovirus and Dengue virus in several ways that impact VADR processing

| | Norovirus | Dengue virus | SARS-CoV-2 |
|-----------------------------------|-----------|--------------|------------|
| length | 7.6Kb | 10.7Kb | 29.9Kb |
| # seqs | 44,936 | 113,211 | 1,616,891 |
| % seqs full length | 5.1% | 8.4% | 99.7% |
| % Ns | 0.5% | 0.2% | 1.4% |
| % seqs with stretch of $>= 50$ Ns | 1.0% | 0.4% | 38.7% |
| average % identity | 81.6% | 94.4% | 99.4% |


VADR v1.0 performance

| seconds per sequence | 42.4 | 92.6 | 331.8 |
|------------------------------|------|------|--------|
| required RAM | 8Gb | 8Gb | 64Gb |
| total running time, CPU days | 1.1 | 10.2 | 6187.6 |

Replacing Ns with expected nucleotides allows many 'good' sequences to pass




Seeded alignment using blastn makes alignment stage faster



Using glsearch instead of cmalign reduces memory requirement

lower memory requirement (2Gb max) allows for multi-threading



VADR is now 1000-fold faster in practice for SARS-CoV-2 processing

| | seeded | Ν | | | | secs | hours | speedup |
|---------|--------|----------|-----------|------|----------|--------|----------|---------|
| VADR | align- | replace- | | # | required | per | per 100K | VS |
| version | ment? | ment? | glsearch? | cpus | RAM | seq | seqs | v1.0 |
| | | | | | | | | |
| v1.0 | _ | _ | _ | 1 | 64 Gb | 329.91 | 9164.3 | _ |

VADR is now 1000-fold faster in practice for SARS-CoV-2 processing

| | | seeded | Ν | | | | secs | hours | speedup |
|---|--------------|--------|-------------|-----------|------|----------|--------|----------|---------|
| | VADR | align- | replace- | | # | required | per | per 100K | VS |
| | version | ment? | ment? | glsearch? | cpus | RAM | seq | seqs | v1.0 |
| • | | | | | | | | | |
| | v1.0 | _ | | _ | 1 | 64 Gb | 329.91 | 9164.3 | _ |
| | | | | | | | | | |
| | $\vee 1.4.1$ | + | + | + | 1 | 2 Gb | 2.51 | 69.8 | 131.4 |

VADR is now 1000-fold faster in practice for SARS-CoV-2 processing

| | seeded | Ν | | | | secs | hours | speedup |
|---------|--------|----------|-----------|------|----------|--------|----------|---------|
| VADR | align- | replace- | | # | required | per | per 100K | VS |
| version | ment? | ment? | glsearch? | cpus | RAM | seq | seqs | v1.0 |
| v1.0 | _ | _ | _ | 1 | 64 Gb | 329.91 | 9164.3 | _ |
| v1.4.1 | + | + | + | 1 | 2 Gb | 2.51 | 69.8 | 131.4 |
| v1.4.1 | + | + | + | 8 | 16 Gb | 0.33 | 9.3 | 986.8 |
| v1.4.1 | + | + | + | 32 | 64 Gb | 0.13 | 3.7 | 2462.2 |

VADR is now fast enough to handle hundreds of thousands of sequences per month

| | | #new | #cumulative |
|------------|--------------|--------------------|------------------------|
| month | year | seqs | seqs |
| Jan | 2020 | 32 | 32 |
| Feb | 2020 | 58 | 90 |
| Mar | 2020 | 332 | 422 |
| Apr | 2020 | 1541 | 1963 |
| May | 2020 | 2974 | 4937 |
| Jun | 2020 | 3394 | 8331 |
| Jul | 2020 | 3604 | 11,935 |
| Aug Sep | 2020 2020 | 3818 6731 | 15,753 |
| Oct | 2020 | 11,939 | 22,484 34,423 |
| Nov | 2020 | 4274 | 38,697 |
| Dec | 2020 | 4530 | 43,227 |
| 200 | 2020 | 1000 | 10,221 |
| Jan | 2021 | 8775 | 52,002 |
| Feb | 2021 | 26,078 | 78,080 |
| Mar | 2021 | 42,607 | 120,687 |
| Apr | 2021 | 97,095 | 217,782 |
| May | 2021 | 104,729 | 322,511 |
| Jun | 2021 | 46,187 | 368,698 |
| Jul | 2021 | 43,336 | 412,034 |
| Aug | 2021 | 141,958 | 553,992 |
| Sep Oct | 2021 | 267,562 | 821,554 |
| Nov | 2021 2021 | 239,296 | 1,060,850 1,328,120 |
| Dec | 2021 | 267,270 288,771 | 1,616,891 |
| DCC | 2021 | 200,111 | 1,010,091 |
| Jan | 2022 | 258,522 | 1,875,413 |
| Feb | 2022 | 230,185 | 2,105,598 |
| | | • | • |

Besides getting faster, VADR has changed in other ways (work with Linda Yankie and Vince Calhoun and GenBank team)

- 14 releases since March 2020
- 3 additional models (all eventually dropped):
 - B.1.1.7 (alpha)
 - B.1.525
 - 28254-deletion
- allow some alerts for non-essential ORFs without failing sequence (they become a misc_feature instead)

Faster SARS-CoV-2 sequence validation and annotation for GenBank using VADR

Eric P. Nawrocki ^{®*}

National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA

Received September 08, 2022; Revised November 28, 2022; Editorial Decision December 14, 2022; Accepted January 03, 2023

- Respiratory Syncitial Virus (RSV) models
- Mpox virus
- Influenza models
 - compare with existing GenBank flu tool FLAN

- Respiratory Syncitial Virus (RSV) models
- Mpox virus
- Influenza models
 - compare with existing GenBank flu tool FLAN

- Respiratory Syncitial Virus (RSV) models
- Mpox virus
- Influenza models
- Zika models (in progress, EB Dicksinson (postbac))
 - matches or exceeds performance of existing GenBank flu tool FLAN
 - able to annotate highly pathogenic avian influenza (H5N1)

Database, 2024, baae091 DOI: https://doi.org/10.1093/database/baae091

Original article



Influenza sequence validation and annotation using VADR

Vincent C. Calhoun, Eneida L. Hatcher, Linda Yankie, Eric P. Nawrocki **

National Center for Biotechnology Information, U.S. National Library of Medicine, National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, United States

- VADR is general, standalone and includes a module for users to build new models
- Alex Greninger's lab at Univ of Washington:
 - sequences a wide variety of human pathogenic viruses
 - previously developed the VAPiD software tool for validating and annotating viral sequences
 - now collaborates with me building VADR models:
 - * Herpes Simplex Virus (HSV-1 and HSV-2) models
 - * Human metapneumovirus (HMPV) models

VADR and NCBI virus

- FY2025 NCBI virus goals related to VADR:
 - VADR web server
 - Replacement of FLAN with VADR

Future directions

| More models (our group and Greninger |
|--|
|--|

Alignment-based models

• RNA structure annotation in Flaviviruses (already exists for Dengue)

Structural RNA sequence analysis

| • intro to Infernal |
|--|
| • intro to Rfam |
| • intro to RNAcentral? |
| • intro to R2DT? |
| RNA annotation: PGAP, Euk genomes (?), Hydractinia genomes |
| • tmRNA DB |
| |